Vancomycin Dosing in Critically Ill Patients: Robust Methods for Improved Continuous-Infusion Regimens
Open Access
- 1 June 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (6), 2704-2709
- https://doi.org/10.1128/aac.01708-10
Abstract
Despite the development of novel antibiotics active against Gram-positive bacteria, vancomycin generally remains the first treatment, although rapidly achieving concentrations associated with maximal efficacy provides an unresolved challenge. The objective of this study was to conduct a population pharmacokinetic analysis of vancomycin in a large population of critically ill patients. This was a retrospective data collection of 206 adult septic critically ill patients who were administered vancomycin as a loading dose followed by continuous infusion. The concentration-versus-time data for vancomycin in serum was analyzed by a nonlinear mixed-effects modeling approach using NONMEM. Monte Carlo simulations were performed using the final covariate model. We found that the best population pharmacokinetic model consisted of a one-compartment linear model with combined proportional and additive residual unknown variability. The volume of distribution of vancomycin (1.5 liters/kg) was described by total body weight and clearance (4.6 liters/h) by 24-hour urinary creatinine clearance (CrCl), normalized to body surface area. Simulation data showed that a 35-mg/kg loading dose was necessary to rapidly achieve vancomycin concentrations of 20 mg/liter. Daily vancomycin requirements were dependent on CrCl, such that a patient with a CrCl of 100 ml/min/1.73 m 2 would require at least 35 mg/kg per day by continuous infusion to maintain target concentrations. In conclusion, we have found that higher-than-recommended loading and daily doses of vancomycin seem to be necessary to rapidly achieve therapeutic serum concentrations in these patients.Keywords
This publication has 33 references indexed in Scilit:
- Comparison of Dopamine and Norepinephrine in the Treatment of ShockThe New England Journal of Medicine, 2010
- Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infectionsExpert Review of Anti-infective Therapy, 2010
- Augmented Renal ClearanceClinical Pharmacokinetics, 2010
- Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory ConcentrationHospital Pharmacy, 2009
- Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill PatientsAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetic issues for antibiotics in the critically ill patientCritical Care Medicine, 2009
- Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*Critical Care Medicine, 2006
- Quantitative justification for target concentration intervention – parameter variability and predictive performance using population pharmacokinetic models for aminoglycosidesBritish Journal of Clinical Pharmacology, 2004
- Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'Nature Reviews Microbiology, 2004
- APACHE IICritical Care Medicine, 1985